NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings results on Tuesday, January, 7th. The medical instruments supplier reported $0.06 EPS for the quarter, beating the consensus estimate of $0.02 by $0.04. The medical instruments supplier had revenue of $70 million for the quarter, compared to the consensus estimate of $71.28 million. AngioDynamics had a net margin of 17.47% and a return on equity of 3.72%. The firm's revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.22 EPS. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY20 earnings guidance on Tuesday, January, 7th. The company provided earnings per share guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.13. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.85 million.

1 analysts have issued 1-year target prices for AngioDynamics' shares. Their forecasts range from $21.00 to $21.00. On average, they expect AngioDynamics' share price to reach $21.00 in the next year. This suggests a possible upside of 69.6% from the stock's current price. View Analyst Price Targets for AngioDynamics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

News stories about ANGO stock have been trending positive on Wednesday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,350,000 shares, an increase of 35.0% from the December 31st total of 1,000,000 shares. Based on an average trading volume of 337,900 shares, the days-to-cover ratio is currently 4.0 days. Approximately 3.7% of the company's stock are short sold. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Oasis Petroleum (OAS), FireEye (FEYE), Intel (INTC), Mattel (MAT), Cal-Maine Foods (CALM), Pattern Energy Group (PEGI), Bank of America (BAC), Centurylink (CTL) and Hanesbrands (HBI).

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (12.72%), Victory Capital Management Inc. (12.19%), State Street Corp (4.06%), Janus Henderson Group PLC (2.96%), Prudential Financial Inc. (1.96%) and Renaissance Technologies LLC (1.74%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Penn Capital Management Co. Inc., New York State Common Retirement Fund, Marshall Wace North America L.P., Alliancebernstein L.P., Oxford Asset Management LLP, KBC Group NV and Tributary Capital Management LLC. View Insider Buying and Selling for AngioDynamics.

ANGO stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Prudential Financial Inc., Bank of Montreal Can, Assenagon Asset Management S.A., Marshall Wace LLP, Renaissance Technologies LLC and State Street Corp. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $12.38.

AngioDynamics has a market capitalization of $465.81 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]